Nano cap Cassava Sciences (NASDAQ:SAVA) jumps 15% premarket on robust volume on the heels of its update on an unsuccessful mid-stage study of PTI-125 in Alzheimer’s disease (AD) patients.
It believes that the trial failed due to the high
variability in biomarker levels over 28 days in the control group, in
addition to other factors. As such, it plans to reanalyze the
cerebrospinal fluid from all subjects.
It also plans to analyze lymphocyte and plasma
samples from all participants aimed at generating direct evidence of
PTI-125 target engagement.
And lastly, it will assess the effects of PTI-125
on cognition which may provide evidence of at least stabilization of
cognitive decline in AD patients.
Results from the relook should be available in H2.
Small molecule PTI-125 targets
an altered form of filamin A, a scaffolding protein found throughout
the body. A highly toxic form of the protein is present in the brains of
AD sufferers which disrupts the normal function of neurons, leading to
neurodegeneration and brain inflammation. PTI-125 is designed to restore
the normal shape of filamin A in the brain, improving the function of
multiple brain receptors and dampening neuroinflammation.
https://seekingalpha.com/news/3579998-cassava-sciences-rallies-on-hopes-for-alzheimers-candiate-ptiminus-125
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.